Tiselizumab’s Mechanism of Action in Patients with Hepatocellular Carcinoma
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses tiselizumab’s mechanism of action in patients with hepatocellular carcinoma.
Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses tiselizumab’s mechanism of action in patients with hepatocellular carcinoma (HCC).
Tiselizumab is an investigational anti-PD1 monoclonal antibody, according to Abou-Alfa. It has a high affinity for PD-1 due to the fact it’s designed to minimize the bindings of FC gamma receptors to microphages. This process limits antibody-dependent phagocytosis.
This allows T cells to come into full play, says Abou-Alfa. However, due to the FC gamma receptors, this may be a more laborious process. With the extra assets provided by tiselizumab, some of the challenges may be alleviated, according to Abou-Alfa.
FDA Receives Resubmitted NDA for Camrelizumab/Rivoceranib Combo in Unresectable HCC
September 24th 2024A new drug application has been resubmitted to the FDA for the combination of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma, following a complete response letter in May 2024.
Read More
